Look for:

Our offer for

GENMAB A/S


ISIN:
DK0010272202
WKN:
-

2024/11/01 08:01:14
Price
204.90 EUR
Difference -0.05% (-0.10)

General attributes

ISINDK0010272202
SymbolGMAB
ExchangeHanover
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)13,051 EUR
BenchmarkOMX COPENHAGEN 20

Market data

Bid (Bid size)207.40 EUR (145)
Ask (Ask size)207.50 EUR (145)
Open204.90 EUR
High204.90 EUR
Low204.90 EUR
Close (prev. day)205.00 EUR
VWAP-
Volume (pcs)0
Trading volume0.00
Number of trades1
Last size0

Futures and Options

Related Futures9
Related Options-

PDF Downloads

Annual report: GENMAB A/SPDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2024/11/01 08:01:14
Price
204.90 EUR
Difference -0.05% (-0.10)

General attributes

ISINDK0010272202
SymbolGMAB
ExchangeHanover
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)13,051 EUR
BenchmarkOMX COPENHAGEN 20

Market data

Bid (Bid size)207.40 EUR (145)
Ask (Ask size)207.50 EUR (145)
Open204.90 EUR
High204.90 EUR
Low204.90 EUR
Close (prev. day)205.00 EUR
VWAP-
Volume (pcs)0
Trading volume0.00
Number of trades1
Last size0

Performance and Risk

6M1Y3Y
Perf (%)-24.07%-22.29%-45.92%
Perf (abs.)-65.00-58.80-174.10
Beta0.160.230.62
Volatility25.7530.3333.12
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)209.66 EUR (0)
Ø price 30 days | Ø volume 30 days (pcs.)212.77 EUR (0)
Ø price 100 days | Ø volume 100 days (pcs.)234.81 EUR (0)
Ø price 250 days | Ø volume 250 days (pcs.)257.79 EUR (0)
YTD High | date295.90 EUR (2024/01/09)
YTD Low | date205.00 EUR (2024/10/31)
52 Weeks High | date300.20 EUR (2023/11/14)
52 Weeks Low | date205.00 EUR (2024/10/31)

All listings for GENMAB A/S

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Vienna Stock Exchange2024/11/0113:00207.00 EUR0.003
Tradegate2024/11/0113:12206.90 EUR0.0512
Stuttgart2024/11/0112:46206.60 EUR0.003
Nasdaq Copenhagen2024/11/0114:131,546.50 DKK43.831,231
Munich2024/11/0108:04205.20 EUR0.001
London Stock Exchange European Trade Reporting2024/11/0109:001,521.25 DKK0.001
Hanover2024/11/0108:01204.90 EUR0.001
Frankfurt2024/11/0109:06203.20 EUR0.001
FINRA other OTC Issues2024/10/3120:36218.47 USD0.2322
Duesseldorf2024/11/0112:30206.80 EUR0.003
Berlin2024/11/0114:13207.30 EUR0.009

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=2495&ID_TYPE_IMAGE_LOGO=2

Contact Details

GENMAB A/S
- -
Carl Jacobsens Vej 30, Valby - 2500 Copenhagen
Telefon: +45-70-20-27-28
Fax: +
E-mail: info@genmab.com

PDF Downloads

Annual report: GENMAB A/SPDF Download

Company Profile

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Members of Management Board

Jan G. J. van de WinkelChairman of Managing Board
Judith KlimovskyMember of Executive Committee
Martine J. van VugtMember of Executive Committee
Anthony ManciniMember of Executive Committee
Anthony PaganoMember of Executive Committee
Birgitte StephensenMember of Executive Committee
Christopher CozicMember of Executive Committee
Tahamtan AhmadiMember of Executive Committee

Board of directors

Deirdre ConnellyChairman of Supervisory Board
Anders Gersel PedersenMember of Supervisory Board
Mijke ZachariasseMember of Supervisory Board
Paolo Augusto PaolettiMember of Supervisory Board
Elizabeth O'FarrellMember of Supervisory Board
Martin SchultzMember of Supervisory Board
Pernille ErenbjergMember of Supervisory Board
Rolf K. HoffmannMember of Supervisory Board
Takahiro HamataniMember of Supervisory Board





Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. For more details please read our Data protection policy.

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Erste Group Bank AG or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites”) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions (the “Interested Party“).

The publication and distribution of information as well as offering and selling of products and services described on the Websites is prohibited by law in some jurisdictions. For this reason, persons in countries in which the publication as well as the offering and selling of products and services described on the Websites are not permitted by law, must not enter the Websites and/or acquire the products displayed on the Websites.

Neither Erste Group nor any third party shall offer access to the Websites or offer the products to especially, but not limited to citizen/residents of the United States and “U.S. person” (as defined in Regulation S under the US Securities Act 1933 as amended). For this reason, the distribution or redistribution of the information, materials and products into United States or into any other jurisdiction where it is not permitted under the applicable law, as well as to the citizens/residents of these countries shall be prohibited. The securities displayed on the Websites have not been and will not be registered under the US Securities Act of 1933 and trading in the securities has not been approved for purposes of the US Commodities Exchange Act of 1936. For this reason the securities may, inter alia, not be offered, sold or delivered within the United States or, for the account and benefit of U.S. persons.

The Interested Party is solely responsible to examine, whether he may enter the Websites under the law applicable to it. Erste Group shall not be responsible for the distribution of content of any of the Websites to individuals or entities which provide false information about their right to enter the Websites. For this reason Erste Group shall not be liable for any legal claims or damages which may result from the unauthorized entering or reading of the Websites.

By agreeing to this hereto, the Interested Party confirms that
(i) It has read, understood and accepted this Information and the Disclaimer;
(ii) It informed itself about any possible legal restriction and warrants that it is not restricted or prohibited to enter the Websites according to any law applicable; and
(iii) It does not make available the contents of the Websites to any person who is not qualified by law to enter the Websites.